Neupro

Parkinson's Disease, Restless Legs Syndrome, Restless Legs Syndrome
Treatment
6 FDA approvals
20 Active Studies for Neupro

What is Neupro

RotigotineThe Generic name of this drug
Treatment SummaryRotigotine (Neupro) is a patch that is worn on the skin and slowly releases medication over 24 hours to treat Parkinson’s Disease and Restless Legs Syndrome. It may also have antidepressant effects. Rotigotine was developed by Aderis Pharmaceuticals and licensed to Schwarz Pharma in 1998. It was approved by the EMA in 2006 and the FDA in 2007, but was recalled in 2008 due to delivery problems. Since then, it has been authorized as a treatment for RLS.
Neuprois the brand name
image of different drug pills on a surface
Neupro Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Neupro
Rotigotine
2012
7

Approved as Treatment by the FDA

Rotigotine, also called Neupro, is approved by the FDA for 6 uses including Moderate restless legs syndrome (RLS) and Severe restless legs syndrome (RLS) .
Moderate restless legs syndrome (RLS)
Helps manage Moderate restless legs syndrome (RLS)
Severe restless legs syndrome (RLS)
Helps manage Severe restless legs syndrome (RLS)
Parkinson's Disease (PD)
Helps manage Parkinson's Disease (PD)
Parkinson's Disease
Helps manage Parkinson's Disease (PD)
Restless Legs Syndrome
Helps manage Moderate restless legs syndrome (RLS)
Restless Legs Syndrome
Helps manage Severe restless legs syndrome (RLS)

Effectiveness

How Neupro Affects PatientsRotigotine binds to dopamine receptors (D1-D5, with the highest affinity to D3) and has effects on other receptors such as alpha-2-adrenergic and 5HT1A. It also stops dopamine from being taken up and prevents the release of prolactin. Studies have found that even at doses up to 24 mg/24 hours, there is no indication of rotigotine causing a prolonged QT/QTc interval. This was confirmed in a trial with male and female patients with advanced-stage Parkinson's disease where a positive-controlled (moxifloxacin) showed assay
How Neupro works in the bodyRotigotine is a drug that mimics the effects of the chemical dopamine. It is administered through a patch worn on the skin that needs to be replaced every 24 hours. Rotigotine works by activating dopamine receptors in the body, although it is not yet clear exactly how it helps treat Restless Legs Syndrome.

When to interrupt dosage

The recommended dosage of Neupro is contingent upon the determined condition, such as Restless Legs Syndrome, Parkinson's Disease and Restless Legs Syndrome. The measure of dosage is dependent upon the technique of delivery (e.g. Patch - Transdermal or Patch) featured in the table beneath.
Condition
Dosage
Administration
Parkinson's Disease
, 0.2 mg/hour, 0.4 mg/hour, 0.3 mg/hour, 0.6 mg/hour, 0.8 mg/hour, 0.1 mg/hour
, Patch, Transdermal, Patch - Transdermal, Patch, extended release, Patch, extended release - Transdermal
Restless Legs Syndrome
, 0.2 mg/hour, 0.4 mg/hour, 0.3 mg/hour, 0.6 mg/hour, 0.8 mg/hour, 0.1 mg/hour
, Patch, Transdermal, Patch - Transdermal, Patch, extended release, Patch, extended release - Transdermal
Restless Legs Syndrome
, 0.2 mg/hour, 0.4 mg/hour, 0.3 mg/hour, 0.6 mg/hour, 0.8 mg/hour, 0.1 mg/hour
, Patch, Transdermal, Patch - Transdermal, Patch, extended release, Patch, extended release - Transdermal

Warnings

There are 20 known major drug interactions with Neupro.
Common Neupro Drug Interactions
Drug Name
Risk Level
Description
Astemizole
Major
The metabolism of Astemizole can be decreased when combined with Rotigotine.
Azelastine
Major
Rotigotine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Dacomitinib
Major
The metabolism of Dacomitinib can be decreased when combined with Rotigotine.
Enasidenib
Major
The metabolism of Enasidenib can be decreased when combined with Rotigotine.
Erlotinib
Major
The metabolism of Erlotinib can be decreased when combined with Rotigotine.
Neupro Toxicity & Overdose RiskOverdosing on a dopamine agonist can cause symptoms such as nausea, vomiting, low blood pressure, involuntary movements, hallucinations, confusion, seizures, and other signs of too much dopamine in the body.
image of a doctor in a lab doing drug, clinical research

Neupro Novel Uses: Which Conditions Have a Clinical Trial Featuring Neupro?

Currently, 45 active clinical trials are investigating the potential of Neupro to alleviate Restless Legs Syndrome, Restless Legs Syndrome and Parkinson's Disease.
Condition
Clinical Trials
Trial Phases
Parkinson's Disease
39 Actively Recruiting
Not Applicable, Phase 1, Phase 4, Phase 2, Phase 3, Early Phase 1
Restless Legs Syndrome
0 Actively Recruiting
Restless Legs Syndrome
6 Actively Recruiting
Phase 4, Not Applicable, Phase 1, Phase 2

Neupro Reviews: What are patients saying about Neupro?

5Patient Review
3/1/2016
Neupro for Parkinson's Disease
Neupro has been awesome for decreasing my tremors and stiffness. The only downside is that it's caused some insomnia; but, all things considered, the pros definitely outweigh the cons.
5Patient Review
5/28/2020
Neupro for Extreme Discomfort in Calves when Sitting or Lying Down
I've been using these patches for four years now and they've done wonders for my restless legs. The only downside is that it doesn't always stick well, depending on where I put it. Other than that, no negative side effects like weight gain or anything else.
5Patient Review
8/22/2016
Neupro for Parkinson's Disease
The patches are more difficult to apply when the backing is on a diagonal cut; I prefer when it's cut at a 90 degree angle.
5Patient Review
12/10/2020
Neupro for Parkinson's Disease
I sleep better than I ever have since taking this medication; however, it has caused constipation to be a problem for me.
5Patient Review
9/29/2015
Neupro for Parkinson's Disease
I have a lot more confidence in this treatment because it provides 24-hour relief.
4.3Patient Review
1/13/2021
Neupro for Extreme Discomfort in Calves when Sitting or Lying Down
While it has caused me some depression and fatigue, this medication is really effective for treating my restless leg syndrome.
4Patient Review
5/27/2015
Neupro for Parkinson's Disease
Neupro has been effective in controlling my PD symptoms; however, I now have difficulty sleeping through the night and often wake up with leg cramps. Are these common side effects that I should expect?
4Patient Review
2/25/2016
Neupro for Parkinson's Disease
After wearing neupro patch for some time, I developed an itchy rash under the patch.
3Patient Review
1/30/2017
Neupro for Extreme Discomfort in Calves when Sitting or Lying Down
This treatment has been helpful for my restless legs, but it's not perfect. The patch falls off pretty easily, so I have to tape it on every day. Some days are better than others, but this definitely isn't a cure-all.
3Patient Review
6/17/2022
Neupro for Extreme Discomfort in Calves when Sitting or Lying Down
The patches are sometimes difficult to keep on, which is an issue because they need to stay on for a full day. That said, when I was able to get them to stick, the treatment effectively relieved my restless leg syndrome.
2.7Patient Review
7/9/2020
Neupro for Parkinson's Disease
I didn't notice any improvements in my balance or walking after a month of using this treatment, and it's quite pricey.
2.3Patient Review
5/10/2021
Neupro for Parkinson's Disease
I found the patches to be very irritating and difficult to keep on. They also caused some skin irritation for me, so I had to stop using them. While I was using them, they did seem to help somewhat.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about neupro

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is NEUPRO patch a narcotic?

"Neupro is a non-controlled substance containing rotigotine. It is a dopamine agonist that is approved to treat Parkinson's disease and restless legs syndrome. The classification is thought to work by stimulating dopamine receptors in the brain."

Answered by AI

What is NEUPRO used for?

"NEUPRO is a prescription medicine used for treating Parkinson's disease and moderate-to-severe primary Restless Legs Syndrome."

Answered by AI

How does NEUPRO make you feel?

"The following are potential side effects of NEUPRO that patients should be aware of: hallucinations, confusion, excessive suspicion, aggressive behavior, agitation, delusional beliefs, and disorganized thinking. These symptoms can either start or worsen when taking NEUPRO."

Answered by AI

What drug class is NEUPRO?

"The active drug in Neupro is rotigotine, which is a dopamine agonist. These drugs work in a similar way and Neupro is applied to the skin as patches every day."

Answered by AI

Clinical Trials for Neupro

Have you considered Neupro clinical trials? We made a collection of clinical trials featuring Neupro, we think they might fit your search criteria.Go to Trials
Image of Kennedy Krieger Institute in Baltimore, United States.

Iron Supplementation for ADHD and Restless Sleep

8 - 18
All Sexes
Baltimore, MD
The goal of this clinical trial is to learn if iron supplementation works to restless sleep in youth with ADHD. A second goal is to learn if iron supplementation helps to ease ADHD symptoms. The main questions that this trial aims to answer are: Does 3 months of iron supplementation treatment improve parent- and youth self-reported sleep difficulties more than placebo? Does 3 months of iron supplementation treatment improve sleep as measured by actigraphy more than placebo? Does 3 months of iron supplementation treatment improve parent-reported and/or objectively measured attention more than placebo? Researchers will compare over-the-counter iron supplementation treatment to a placebo (a look-alike substance that contains no drug) to see if iron supplementation works to treat sleep difficulties in youth with ADHD. Participants will: * Take iron supplements every day for 3 months * Visit the clinic once before treatment begins and once at the end of treatment to complete tests and rating scales related to sleep and attention * Wear motion-monitoring leg bands while sleeping for one 2-week period before treatment begins and one 2-week period at the end of treatment
Phase 1 & 2
Waitlist Available
Kennedy Krieger InstituteAlison E Pritchard, PhD
Image of Centre for Brain and Mind, Western University in London, Canada.

Cognitive Cueing + Video Intervention for Parkinson's Disease

40 - 99
All Sexes
London, Canada
The goal of this clinical trial is to learn if cognitive cueing (eg., prompting individuals to think about taking big-long steps while walking), either as a stand- alone intervention or combined with a personalized gait training video, can improve gait (walking), mobility, and balance confidence for individuals with Parkinson's Disease. The main questions it aims to answer are: 1. Does focusing on cognitive cues while walking improve gait, mobility, and balance confidence for individuals with Parkinson's Disease? 2. Does incorporating a personalized gait training video alongside cognitive cueing lead to amplified improvements in gait, mobility, and balance confidence for individuals with Parkinson's Disease? Researchers will compare how gait, mobility, balance confidence and quality of life change over time for participants when they practice walking with and without a cognitive cue alone, and when they practice with using a personalized gait training video. The researchers are also interested in how participation in this trial will affect quality of life and conscious attention to gait. Participants will * Complete walking trials on an instrumented mat that records data on their walking ability. These trials will be undertaken without a cognitive cue and while participants mentally rehearse a series of 3 cognitive cues (Take big long steps; Walk heel-toe; Stand up straight). * Be informed about which of the 3 cues best improved their walking and will receive a personalized gait training video for at home practice. * Complete online surveys that ask questions about their Parkinson's Disease, mobility, balance confidence quality of life and conscious attention to gait. * Visit the research facility 3 to 4 times during the study to have their gait (walking), mobility, balance confidence, quality of life and conscious attention to gait assessed and reassessed. * Practice both with and without their personalized video at home and keep a diary to record their practice sessions * Participate in a brief interview to discuss their experiences with the training and their perceptions of the effectiveness of cognitive cues and video-recorded feedback
Waitlist Available
Has No Placebo
Centre for Brain and Mind, Western University
Image of Sunnybrook Health Sciences Centre in Toronto, Canada.

Cannabis for Restless Legs Syndrome

18+
All Sexes
Toronto, Canada
Restless Legs Syndrome (RLS) is a disorder that causes painful and uncomfortable sensations in the legs, and its symptoms have a significant impact on sleep and quality of life. Cannabis has been used by some RLS patients as a treatment due to its painkilling and drowsiness effects, however there has never been a clinical research trial investigating cannabis in patients with RLS. A controlled trial is needed to establish how safe and feasible cannabis is as a treatment for RLS. The investigators plan to randomize 30 participants with moderate-to-severe RLS to receive either cannabis or placebo for 8 weeks. The investigators will measure patients sleep quality and quality of life at baseline and 8-week follow-up. The investigators will also monitor patients for any adverse reactions to the study drug.
Recruiting
Drug
Sunnybrook Health Sciences Centre (+1 Sites)
Have you considered Neupro clinical trials? We made a collection of clinical trials featuring Neupro, we think they might fit your search criteria.Go to Trials
Image of University of Kentucky in Lexington, United States.

Peripheral Nerve Tissue Implantation for Parkinson's Disease

45 - 75
All Sexes
Lexington, KY
The investigators propose a Phase I single surgical-center, double-blinded randomized parallel clinical trial involving bilateral autologous peripheral nerve tissue (PNT) delivery into the NBM or the alternate target also affecting cognition in this population, the substantia nigra (SN), to address "repair cell" support of these areas. Twenty-four participants with idiopathic Parkinson's Disease (PD) who have selected, qualified and agreed to receive as standard of care deep brain stimulation (DBS) will be enrolled and randomly allocated to receive bilateral PNT deployment to either the NBM or SN at the time of DBS surgery. Participants will be allocated equally among both assignments over the course of three years (8 Year 1, 10 Year 2, 6 Year 3). Participants will be evaluated for neurocognitive, motoric function, activities of daily living, and quality of life at enrollment before surgery, two-weeks after surgery, and 6, 12, and 24 months after surgery.
Phase 1
Recruiting
University of KentuckyCraig G van Horne, MD, PhD
Image of Austin Clinic PPD in Austin, United States.

LY3962681 for Parkinson's Disease

30 - 80
All Sexes
Austin, TX
The purpose of this study is to evaluate the safety, tolerability, and PK/PD of LY3962681 in healthy volunteers and patients with Parkinson's disease. The study will be comprised of two parts, the Single Ascending Dose (SAD) study and the Multiple Ascending Doses (MAD) study. During the SAD portion of the study, healthy volunteers will receive a single dose of LY3962681 or placebo (artificial cerebrospinal fluid (aCSF), no active drug) given into the spinal fluid. During the MAD portion of the study, patients with Parkinson's disease will receive two doses of either LY3962681 or placebo (aCSF) administered into the spinal fluid. * The treatment period in the SAD study will be 1 day. The treatment period in the MAD study will be 2 days, 12 to 24 weeks apart. * The follow-up period in the SAD study will be up to 52 weeks. The follow-up period in the MAD study will be up to 52 weeks post Dose 2.
Phase 1
Recruiting
Austin Clinic PPDTravis LewisPrevail Therapeutics
Image of Edward Hines Jr. VA Hospital, Hines, IL in Hines, United States.

Non-Invasive Vagal Nerve Stimulation for Parkinson's Disease

50 - 88
All Sexes
Hines, IL
More than 110,000 US Veterans living with Parkinson's disease (PD) currently receive PD-related care and services from the VA. Fall prevention is a priority for Veterans living PD. Gait disturbances are a major cause for functional dependence and the largest risk factor for falls, institutionalization, and death in PD. This SPiRE addresses the need to advance nonpharmacological rehabilitative health care of Veterans and maximizing functional outcomes by developing a non-invasive, neuromodulatory transcutaneous cervical Vagal Nerve Stimulation as an at-home intervention to improve gait and balance. This pilot clinical trial will assist with future efforts and priorities of the VA to prolong independent living and quality of life by minimizing gait and balance dysfunction experienced by Veterans living with PD.
Waitlist Available
Has No Placebo
Edward Hines Jr. VA Hospital, Hines, ILSandra L. Kletzel, PhD BA
Have you considered Neupro clinical trials? We made a collection of clinical trials featuring Neupro, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security